美多巴联合普拉克索治疗对帕金森患者运功功能的影响及安全性分析

The efficacy and safety of the combination ofmadopar and pramipexole in patients with Parkinson’s disease

目的:探讨美多巴联合普拉克索治疗对帕金森(PD)患者运动功能的影响,并分析其安全性。方法:选择2015年1月至2018年1月于陕西省杨凌示范区医院接受治疗的82例PD患者为研究对象,按照随机数字表法将其均分为实验组与对照组,每组41例。对照组患者采取美多巴进行治疗,实验组患者采取美多巴联合普拉克索治疗,两组患者治疗时间均为12周,比较两组治疗总有效率,以及两组患者治疗前、后帕金森Hoehn-Yahr分期、统一帕金森病评定量表评分中第Ⅲ部分运动检查评分(UPDRSⅢ)、韦氏综合评定量表(Webster评分)和副反应量表(TESS)评分。结果:实验组治疗总有效率为56.10%(23/41),显著高于对照组的39.02%(16/41)(P<0.05)。治疗后,实验组Hoehn-Yahr分期Ⅲ、Ⅳ、Ⅴ期患者比率显著低于对照组,UPDRSⅢ及TESS评分明显低于对照组(均P<0.05)。结论:美多巴联合普拉克索对PD具有良好的治疗效果,同时具有较高的安全性。

Objective: To explore the clinical effect of madopa combined with pramipexole on motor function in patients with Parkinson’s disease (PD), and to analyze the safety of treatment. Methods: A total of 82 PD patients treated in our hospital from January 2015 to January 2018 were selected, and randomly divided into an experimental group and a control group, with 41 cases in each group. The patients in the control group were treated with madopa, and those in the experimental group were treated with madopa combined with pramipexole for 12 weeks. The total effective rate, PD Hoehn-Yahr staging, Unified PD Rating Scale (UPDRS) part Ⅲ score, Webster score and Treatment Emergent Side effect Scale (TESS) score were compared between the two groups. Results: The total effective rate was 56.10%(23/41) in the experimental group and 39.02%(16/41) in the control group, and the difference between the two groups was statistically significant ( P <0.05). After treatment, the proportion of patients in Hoehn-Yahr stage Ⅲ,Ⅳ and Ⅴ, the UPDRS part Ⅲ score and TESS score in the experimental group were lower than those in the control group ( P <0.05). Conclusion: Medopa combined with pramipexole was effective and safe in the treatment of PD.